BiotechTube

KHK4083

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatitis, Atopic

Conditions

Dermatitis, Atopic

Trial Timeline

Apr 10, 2017 → Feb 7, 2018

NCT ID
NCT03096223

About KHK4083

KHK4083 is a phase 1 stage product being developed by Kyowa Kirin for Dermatitis, Atopic. The current trial status is completed. This product is registered under clinical trial identifier NCT03096223. Target conditions include Dermatitis, Atopic.

What happened to similar drugs?

20 of 20 similar drugs in Dermatitis, Atopic were approved

Approved (20) Terminated (0) Active (0)
✅LebrikizumabEli LillyApproved
✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅tacrolimus ointment + placebo ointmentAstellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03096223Phase 1Completed

Competing Products

20 competing products in Dermatitis, Atopic

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
40
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
40
LebrikizumabEli LillyApproved
50
LebrikizumabEli LillyPhase 3
40
Lebrikizumab + PlaceboEli LillyPhase 3
44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
19
LebrikizumabEli LillyPhase 3
40
ASN008Formation BioPhase 2
25
ENS-002Concerto BiosciencesPhase 1
11
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
35
DS-2741a + PlaceboDaiichi SankyoPhase 1
21
SUN13834 + PlaceboDaiichi SankyoPhase 2
35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
35
tacrolimus ointmentAstellas PharmaPhase 3
40
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
43
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaApproved
43
Tacrolimus Ointment 0.1%Astellas PharmaPhase 2
35